| Liraglutide was a new kind of glicagon like peptide-1 (GLP-1), which could decrease the blood glucose and glycated
hemoglobin levels rapidly, efficiently and lastingly, and had some effects on improving the islet cell function, regulating systolic pressure,
protecting cardiovascular, lowing blood lipids, decreasing body weight, delaying gastric emptying, increasing satiety and so on. In
addition, liraglutide could promote the secretion of insulin on a glucose-dependent manner, and it could stimulate the release of insulin
only in high blood glucose levels, but when patients' blood glucose returned to normal, the effect of GLP-1 would disappeare, thus the
incidence of hypoglycemia was lowered, and the state of diabetes was improved, which had become the hot spot of the field of treatment
of type 2 diabetes. This article mainly reviewed the clinical research progress of liraglutide in the treatment of type 2 diabetes. |
